Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
In response to the company posting pleasing third-quarter results and boosting guidance, shares of Halozyme Therapeutics (NASDAQ: HALO), a biotech that focuses on making other drugs more effective, jumped 13% as of 1:45 p.m. EST.
Here's an overview of the headline numbers from the quarter.
The upbeat quarterly results enabled management to make a number of positive changes to its full-year guidance:
Source: Fool.com
Halozyme Therapeutics Inc. Stock
€48.21
0.360%
Halozyme Therapeutics Inc. is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
As a result the target price of 49 € shows a slightly positive potential of 1.64% compared to the current price of 48.21 € for Halozyme Therapeutics Inc..
